These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018 [TBL] [Abstract][Full Text] [Related]
3. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874 [TBL] [Abstract][Full Text] [Related]
4. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288 [TBL] [Abstract][Full Text] [Related]
5. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy. Chacon JA; Sarnaik AA; Chen JQ; Creasy C; Kale C; Robinson J; Weber J; Hwu P; Pilon-Thomas S; Radvanyi L Clin Cancer Res; 2015 Feb; 21(3):611-21. PubMed ID: 25472998 [TBL] [Abstract][Full Text] [Related]
6. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand. Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858 [TBL] [Abstract][Full Text] [Related]
7. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716 [TBL] [Abstract][Full Text] [Related]
8. Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination. Fromm G; de Silva S; Giffin L; Xu X; Rose J; Schreiber TH Cancer Immunol Res; 2016 Sep; 4(9):766-78. PubMed ID: 27364122 [TBL] [Abstract][Full Text] [Related]
9. CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy. Chen S; Fan J; Zhang M; Qin L; Dominguez D; Long A; Wang G; Ma R; Li H; Zhang Y; Fang D; Sosman J; Zhang B Nat Commun; 2019 Jan; 10(1):150. PubMed ID: 30635578 [TBL] [Abstract][Full Text] [Related]
10. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells. Zhao Y; Croft M Immunol Lett; 2012 Jan; 141(2):220-6. PubMed ID: 22037570 [TBL] [Abstract][Full Text] [Related]
11. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866 [TBL] [Abstract][Full Text] [Related]
12. 4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo. Li Q; Ai J; Song Z; Liu J; Shan B Cell Mol Immunol; 2008 Oct; 5(5):379-84. PubMed ID: 18954562 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model. Guillerey C; Nakamura K; Pichler AC; Barkauskas D; Krumeich S; Stannard K; Miles K; Harjunpää H; Yu Y; Casey M; Doban AI; Lazar M; Hartel G; Smith D; Vuckovic S; Teng MW; Bergsagel PL; Chesi M; Hill GR; Martinet L; Smyth MJ JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31194697 [TBL] [Abstract][Full Text] [Related]